KRAS and adenocarcinoma: Combination therapy trials with docetaxel (GALAXY 1 and 2) led to better outcomes in patients with adenocarcinomas, than docetaxel single agent therapy, but not in the subgroup of KRAS‐mutated tumors (Bhattacharya et al., 2015).